

Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2

NCT05854433

Status RECRUITING
Sponsor Wake Forest University Health Sciences
Enrollment 100 participants

Key Eligibility Criteria

Inclusion (14)

- Age 30-65 years old
- Diagnosis of DM1 or DM2 is based on genetic testing and/or clinical criteria. If the diagnosis is based on clinical criteria, positive DM2 genetic testing is required in first-degree relatives
- Symptoms or clinical findings of proximal muscle weakness
- Ambulate independently (a cane or walking stick is permitted)
- Able to provide informed consent for participation in the study
- ... and 9 more (see full listing online)

Exclusion (17)

- Congenital or juvenile-onset DM1 (onset of first symptom < 20-year-old)
- Individuals with a prior diagnosis of dementia, seizure, stroke, multiple sclerosis, Parkinson's Disease, or other neurodegenerative diseases
- Individuals with active psychiatric illness or alcohol/substance abuse.
- On medications with substantial sedative or cognitive side effects unless the doses have been stable for at least 3 months before the study visit.
- Inability or unwillingness to give written informed consent.
- ... and 12 more (see full listing online)

Locations (1 total)

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

<https://clinicaltrials.gov/study/NCT05854433>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).